Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion

Tumor hypoxia and hypoxic adaptation of cancer cells represent major barriers to successful cancer treatment. We revealed that improved antioxidant capacity contributes to increased radioresistance of cancer cells with tolerance to chronic-cycling severe hypoxia/reoxygenation stress. We hypothesized...

Full description

Bibliographic Details
Main Authors: Christine Hansel, Julian Hlouschek, Kexu Xiang, Margarita Melnikova, Juergen Thomale, Thomas Helleday, Verena Jendrossek, Johann Matschke
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/10/11/3040
_version_ 1797510770565578752
author Christine Hansel
Julian Hlouschek
Kexu Xiang
Margarita Melnikova
Juergen Thomale
Thomas Helleday
Verena Jendrossek
Johann Matschke
author_facet Christine Hansel
Julian Hlouschek
Kexu Xiang
Margarita Melnikova
Juergen Thomale
Thomas Helleday
Verena Jendrossek
Johann Matschke
author_sort Christine Hansel
collection DOAJ
description Tumor hypoxia and hypoxic adaptation of cancer cells represent major barriers to successful cancer treatment. We revealed that improved antioxidant capacity contributes to increased radioresistance of cancer cells with tolerance to chronic-cycling severe hypoxia/reoxygenation stress. We hypothesized, that the improved tolerance to oxidative stress will increase the ability of cancer cells to cope with ROS-induced damage to free deoxy-nucleotides (dNTPs) required for DNA replication and may thus contribute to acquired resistance of cancer cells in advanced tumors to antineoplastic agents inhibiting the nucleotide-sanitizing enzyme MutT Homologue-1 (MTH1), ionizing radiation (IR) or both. Therefore, we aimed to explore potential differences in the sensitivity of cancer cells exposed to acute and chronic-cycling hypoxia/reoxygenation stress to the clinically relevant MTH1-inhibitor TH1579 (Karonudib) and to test whether a multi-targeting approach combining the glutathione withdrawer piperlongumine (PLN) and TH1579 may be suited to increase cancer cell sensitivity to TH1579 alone and in combination with IR. Combination of TH1579 treatment with radiotherapy (RT) led to radiosensitization but was not able to counteract increased radioresistance induced by adaptation to chronic-cycling hypoxia/reoxygenation stress. Disruption of redox homeostasis using PLN sensitized anoxia-tolerant cancer cells to MTH1 inhibition by TH1579 under both normoxic and acute hypoxic treatment conditions. Thus, we uncover a glutathione-driven compensatory resistance mechanism towards MTH1-inhibition in form of increased antioxidant capacity as a consequence of microenvironmental or therapeutic stress.
first_indexed 2024-03-10T05:35:59Z
format Article
id doaj.art-07f7324524244c37ac7f0b3d2d3fe5b2
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-10T05:35:59Z
publishDate 2021-11-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-07f7324524244c37ac7f0b3d2d3fe5b22023-11-22T22:50:26ZengMDPI AGCells2073-44092021-11-011011304010.3390/cells10113040Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione DepletionChristine Hansel0Julian Hlouschek1Kexu Xiang2Margarita Melnikova3Juergen Thomale4Thomas Helleday5Verena Jendrossek6Johann Matschke7Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyScience for Life Laboratory, Karolinska Institutet, 17121 Stockholm, SwedenInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyInstitute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, GermanyTumor hypoxia and hypoxic adaptation of cancer cells represent major barriers to successful cancer treatment. We revealed that improved antioxidant capacity contributes to increased radioresistance of cancer cells with tolerance to chronic-cycling severe hypoxia/reoxygenation stress. We hypothesized, that the improved tolerance to oxidative stress will increase the ability of cancer cells to cope with ROS-induced damage to free deoxy-nucleotides (dNTPs) required for DNA replication and may thus contribute to acquired resistance of cancer cells in advanced tumors to antineoplastic agents inhibiting the nucleotide-sanitizing enzyme MutT Homologue-1 (MTH1), ionizing radiation (IR) or both. Therefore, we aimed to explore potential differences in the sensitivity of cancer cells exposed to acute and chronic-cycling hypoxia/reoxygenation stress to the clinically relevant MTH1-inhibitor TH1579 (Karonudib) and to test whether a multi-targeting approach combining the glutathione withdrawer piperlongumine (PLN) and TH1579 may be suited to increase cancer cell sensitivity to TH1579 alone and in combination with IR. Combination of TH1579 treatment with radiotherapy (RT) led to radiosensitization but was not able to counteract increased radioresistance induced by adaptation to chronic-cycling hypoxia/reoxygenation stress. Disruption of redox homeostasis using PLN sensitized anoxia-tolerant cancer cells to MTH1 inhibition by TH1579 under both normoxic and acute hypoxic treatment conditions. Thus, we uncover a glutathione-driven compensatory resistance mechanism towards MTH1-inhibition in form of increased antioxidant capacity as a consequence of microenvironmental or therapeutic stress.https://www.mdpi.com/2073-4409/10/11/3040chronic cycling hypoxiaradiation resistancemetabolic reprogrammingantioxidant capacityredox homeostasisionizing radiation
spellingShingle Christine Hansel
Julian Hlouschek
Kexu Xiang
Margarita Melnikova
Juergen Thomale
Thomas Helleday
Verena Jendrossek
Johann Matschke
Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
Cells
chronic cycling hypoxia
radiation resistance
metabolic reprogramming
antioxidant capacity
redox homeostasis
ionizing radiation
title Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
title_full Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
title_fullStr Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
title_full_unstemmed Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
title_short Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion
title_sort adaptation to chronic cycling hypoxia renders cancer cells resistant to mth1 inhibitor treatment which can be counteracted by glutathione depletion
topic chronic cycling hypoxia
radiation resistance
metabolic reprogramming
antioxidant capacity
redox homeostasis
ionizing radiation
url https://www.mdpi.com/2073-4409/10/11/3040
work_keys_str_mv AT christinehansel adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT julianhlouschek adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT kexuxiang adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT margaritamelnikova adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT juergenthomale adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT thomashelleday adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT verenajendrossek adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion
AT johannmatschke adaptationtochroniccyclinghypoxiarenderscancercellsresistanttomth1inhibitortreatmentwhichcanbecounteractedbyglutathionedepletion